Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can precise radiation help when breast cancer spreads to just a few places?

NCT ID NCT07397585

Knowledge-focused Sponsor: Istituto Clinico Humanitas Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a precise type of radiation called SBRT can help people with breast cancer that has spread to only a few spots in the body (oligometastatic). Researchers will review medical records from 300 patients to see if SBRT improves how long the cancer stays under control and how long patients live. The goal is to gather more evidence on whether this non-invasive treatment is a good option alongside standard therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stereotactic body radiotherapy (SBRT)
What this could lead to
If this study shows SBRT helps control the cancer and extend survival, it could support using targeted radiation as a standard treatment for limited metastatic breast cancer.
What could go wrong
This is a retrospective study, so it looks back at past data rather than testing a new treatment in a controlled way. Results may be less reliable and not prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with Oligometastatic or oligoprogressive metastatic breast cancer treated with SBRT

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥18 years * Histological diagnosis of breast cancer * Oligometastatic or oligoprogressive metastatic breast cancer * SBRT delivered to a minimum dose of 50Gy EQD2 (αβ 10 Gy),in a maximum of 12 fractions as per Oligocare definition * Ability to provide written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Oligometastasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    28 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O.U. "G. Martino" - Università degli Studi di Messina

    NOT_YET_RECRUITING

    Messina, Messina, 98124, Italy

  • Aorn San Pio

    NOT_YET_RECRUITING

    Benevento, Benevento, 82100, Italy

  • Azienda Ospedaliera San Giovanni Addolorata

    NOT_YET_RECRUITING

    Roma, RM, 00184, Italy

  • Azienda Ospedaliera Sant'Andrea

    NOT_YET_RECRUITING

    Roma, Roma, 00189, Italy

  • Azienda Ospedaliera Universitaria Careggi

    NOT_YET_RECRUITING

    Florence, Firenze, 50134, Italy

  • Azienda Ospedaliera Universitaria Pisana

    NOT_YET_RECRUITING

    Pisa, PI, 56124, Italy

  • Civico Palermo

    NOT_YET_RECRUITING

    Palermo, Palermo, 90127, Italy

  • Fondazione I.R.C.C.S Istituto Nazionale Tumori di Milano

    RECRUITING

    Milan, MILANO, 20133, Italy

  • Fondazione PTV Policlinico Tor Vergata

    NOT_YET_RECRUITING

    Roma, Roma, 00133, Italy

  • Fondazione Policlinico Universitario, Campus-Biomedico

    RECRUITING

    Roma, Roma, 00128, Italy

  • Humanitas Gavazzeni

    RECRUITING

    Bergamo, Bergamo, 24125, Italy

  • IEO

    NOT_YET_RECRUITING

    Milan, Milano, 20141, Italy

  • INT IRCCS Fondazione G. Pascale

    RECRUITING

    Naples, Napoli, 80131, Italy

  • IRCCS Centro di Riferimento Oncologico di Aviano

    NOT_YET_RECRUITING

    Aviano, Pordenone, 33081, Italy

  • IRCCS Humanitas Research Humanitas

    RECRUITING

    Rozzano, MILANO, 20089, Italy

  • IRCCS Ospedale San Raffaele

    NOT_YET_RECRUITING

    Milan, Milan, 20132, Italy

  • Irccs Crob

    RECRUITING

    Rionero in Vulture, PZ, 85028, Italy

  • Irccs Ospedale Policlinico San Martino

    NOT_YET_RECRUITING

    Genova, Genova, 16132, Italy

  • Istituto Oncologico Veneto

    NOT_YET_RECRUITING

    Padova, PD, 35128, Italy

  • Ospedale Maggiore della Carita

    RECRUITING

    Novara, NOVARA, 28100, Italy

  • Ospedale Perrino

    NOT_YET_RECRUITING

    Brindisi, BR, 72100, Italy

  • Radioterapia Oncologica - Ospedale Sanata Chiara

    NOT_YET_RECRUITING

    Trento, TRENTO, 38122, Italy

  • Responsible Research Hospital

    RECRUITING

    Campobasso, CB, 86100, Italy

  • S.C. Radioterapia Oncologica - Azienda Ospedaliera Santa Maria Terni

    NOT_YET_RECRUITING

    Terni, TR, 05100, Italy

  • S.C. Radioterapia Oncologica ASL Taranto

    NOT_YET_RECRUITING

    Taranto, Taranto, 74100, Italy

  • Spedali Civili

    RECRUITING

    Brescia, BS, 25123, Italy

  • UOC Radioterapia Ospedale San Filippo Neri

    NOT_YET_RECRUITING

    Roma, RM, 00135, Italy

  • Uo Radioterapia Aor San Carlo

    NOT_YET_RECRUITING

    Potenza, PZ, 85100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.